GLP1R and type 2 diabetes mellitus: Potential beneficial effects in older and frailer patients tend to be underestimated due to comorbidities, competing risk, and lower representation in randomized trials: the mean age of patients enrolled in GLP-1 RA CVOTs ranged 60–66 years.13,14 The association with long-standing T2DM, poor glycaemic control, and the use of other glucose-lowering drugs might reflect GLP-1 RA not being considered yet first-line treatments for T2DM, and consistently they are still recommended after metformin according to Swedish local guidelines.